Jupi Powder Veterinary Grade API is a multi-route veterinary active pharmaceutical ingredient supplied as a white to off-white crystalline powder for downstream processing into tablets, injectable solutions, capsules, oral powders, granules, feed premixes, and bulk solutions. The product designation carries no separate numerical model code in the available manufacturer documentation; the material is instead qualified by route-specific specification packages that include polymorph identity, particle-size distribution, bulk and tapped density, water content, residual solvents, related substances, elemental impurities, bioburden, and bacterial endotoxin. Manufacture is performed under current good manufacturing practice for veterinary medicinal products, with batch records referenced to VICH guidance and current pharmacopoeial general chapters. The powder is intended for further pharmaceutical processing and is not supplied as a sterilized API; terminal sterilization or aseptic processing of the finished dosage form remains the responsibility of the downstream manufacturer. Across multi-route veterinary manufacturing, differentiation from conventional single-route APIs is based on the breadth of route-appropriate analytical control rather than on a single formulation claim. For tablet and capsule operations, the powder may be processed by direct compression or wet granulation; for injectable and solution presentations, dissolution, clarity, pH, and sub-visible particulate behavior are assessed in the finished product. For feed premix and oral powder applications, flow, bulk density, and blend uniformity are controlled on production-scale equipment. The material is packaged in double low-density polyethylene liners inside a sealed aluminium foil laminate to maintain water content during shipment and storage. Storage is specified at or below 25 °C and below 60% relative humidity unless route-specific stability data support alternative conditions. In the control laboratory, the powder is sampled according to a square-root-of-n-plus-one scheme, with the number of containers defined in the GMP batch record and finished-product sampling plan. Release testing includes identification by infrared absorption spectrophotometry and X-ray powder diffraction, assay by liquid chromatography, optical rotation where applicable, and determination of residual solvents by headspace gas chromatography. These methods are selected from Ph. Eur. 2.2.24, Ph. Eur. 2.9.33, and Ph. Eur. 2.2.29; elemental impurities are tested by Ph. Eur. 2.4.20 or USP <232>/<233> as appropriate. Published data for the specific Jupi Powder batch series are limited; therefore the manufacturer’s certificate of analysis is the controlling reference for numerical values.

How Does the Veterinary-Grade Particle-Size Profile Affect Solid Oral Dosage Manufacturing?

For solid oral dosage manufacturing, particle-size distribution influences flow, compressibility, and dissolution rate in tablets and capsules. The powder is characterized by laser diffraction in accordance with Ph. Eur. 2.9.31, with d10, d50, and d90 reported in the batch release documentation. In direct compression, a narrow distribution with a d90 target below the die-filling threshold of the tablet press is preferred; typical veterinary tablet dies between 8 mm and 13 mm can tolerate d90 values near 250 µm, but flow variability increases when the fines fraction falls below 10% by volume or when the bulk density varies by more than ±10% between batches. Jupi Powder Veterinary Grade API is processed with a controlled milling and sieving step to reduce oversized particles; the specific d90 acceptance range is lot-specific and must be read from the certificate of analysis. Because capsule filling and tableting die-fill depend on powder density, bulk and tapped density are measured according to Ph. Eur. 2.9.34, and the Hausner ratio is calculated from the measured values. A Hausner ratio between 1.00 and 1.25 is generally interpreted as acceptable flow for direct compression, while values above 1.35 indicate cohesive behavior requiring mechanical force-feeding or granulation. Lot-to-lot consistency is more important for pressurized die filling than a single absolute density value. For capsules, the same particle-size and density dataset is used to set tamping pin depth and dosator volume on filling machines. If the powder is subjected to wet granulation, particle-size distribution after milling is controlled separately from the API release specification because the granule size, not the API particle size, governs die filling.

Release dimension	Method/Standard	Route-specific purpose
Identity / polymorph	Ph. Eur. 2.2.24, Ph. Eur. 2.9.33	Confirms crystal form and absence of batch-shift in milling.
Particle-size distribution	Ph. Eur. 2.9.31	Controls flow, dissolution, and segregation in premix/powder.
Bulk and tapped density	Ph. Eur. 2.9.34	Sets tableting and capsule filling parameters.
Water content	Ph. Eur. 2.2.32	Protects against hydrolysis, caking, and wet granulation variability.
Residual solvents	VICH GL18 / Ph. Eur. 5.4	Confirms solvent clearance for veterinary use.
Related substances	Ph. Eur. 2.2.29	Quantifies process impurities and degradation products.
Elemental impurities	Ph. Eur. 2.4.20 / USP <232>–<233>	Limits metal residues relevant to parenteral and feed routes.
Microbial enumeration	Ph. Eur. 2.6.12, 2.6.13	Differentiates oral/feed and injectable-grade limits.
Bacterial endotoxins	Ph. Eur. 2.6.14 / USP <85>	Defines parenteral and solution suitability.
Sterility of finished product	Ph. Eur. 2.6.1	Applies to injectable dosage form after terminal sterilization or aseptic fill.

For premix and granule processing, the powder is blended with milled feed carriers, mineral diluents, or water-soluble excipients using a ribbon blender or a double-cone blender of the type rated at 500 L working capacity. Blend uniformity is evaluated at multiple sampling points after a fixed mixing time; a common veterinary premix in-process criterion is assay recovery within 90.0–110.0% of label claim and relative standard deviation not greater than 5.0% for ten or more samples, although the specific Jupi Powder protocol may use tighter limits. The powder should not be discharged into metal-contact bins that have not been passivated if the molecule is acid-sensitive; published data for this specific API’s contact-surface sensitivity are limited, so compatibility with bin coatings should be confirmed. At relative humidity above 60%, the API may absorb sufficient moisture to raise the water content beyond the release limit, and processing under dehumidified air or nitrogen is advisable. With a high-shear granulator, granulation is carried out using an impeller tip speed of 4–8 m/s and a chopper speed of 1500–2500 rpm, followed by wet milling and fluid-bed drying to a loss on drying end point that is specific to the formulation. The endpoint is monitored by Ph. Eur. 2.2.32 on milled granules. Because the powder contains no added surfactant, the formulator should verify wettability by contact-angle measurement or the drop-penetration method before committing to full-scale manufacturing. If the wet massing water level is increased by more than 3% by weight, a sharp increase in granule hardness is a known risk in high-shear systems; the resulting disintegration shift must be checked against the finished-product specification.

Injectable Solution Manufacture and the Endotoxin Count Constraint for Veterinary APIs

When injectable presentation is required, the API is not sterile at the powder stage, and the finished dosage form must pass sterility testing according to Ph. Eur. 2.6.1. Dissolution of the powder in Water for Injection is performed under controlled temperature, usually 15–25 °C unless solubility data support elevated temperatures. The resulting bulk solution is filtered through a 0.22 µm PVDF or polyethersulfone membrane and filled into depyrogenated vials. The bacterial endotoxin limit for the API solution is derived from the intended veterinary dose and the maximum permitted endotoxin level per kilogram of body mass; the powder is tested by Ph. Eur. 2.6.14 or USP <85> so that the calculated final-product limit is not exceeded. If the dosage form is intended for intramammary or intra-articular administration in food-producing or companion species, additional endotoxin restrictions and particulate limits may apply. In injectable solution manufacture, sub-visible particulate matter in the finished product is evaluated by light obscuration particle count according to Ph. Eur. 2.9.19 or USP <788>. The API batch record should demonstrate clarity and particle burden of the dissolved powder before final filtration; however, published data for this specific configuration are limited, and full-scale filtration validation is required. The product should not be exposed to strong oxidizing agents or concentrated mineral acids during dissolution, because these can generate degradation products that are not part of the registered impurity profile. The pH of the bulk solution is controlled by a buffering system that is selected according to the drug substance’s pKa and the solubility curve; the pH adjustment limits must be stated in the batch manufacturing record. At 121 °C for 15 minutes, terminal sterilization may be applied only if thermal degradation data demonstrate that assay and related substances remain within acceptance limits. If the molecule is thermolabile, aseptic filtration and filling into sterile containers are required, and the API powder must be handled in a classified area from the point of dissolution onward. The powder’s water content, measured by Ph. Eur. 2.2.32, should be sufficiently low to prevent vial-headspace moisture condensation during lyophilization when a freeze-dried injectable presentation is used. For freeze-dried formulations, the cake appearance, reconstitution time, and moisture content of the lyophilized plug are controlled by the finished-product specification. Compared with simple milled powders intended only for oral premix use, the Jupi Powder is controlled for the low residual solvent and low metal profiles that are relevant to parenteral and solution routes. Single-route feed-grade powders frequently accept broader bulk-density variation and higher total aerobic microbial counts; such material is not automatically suitable for sterile or non-sterile injectable preparation without further purification. This API is differentiated by the fact that the same controlled dry powder can be directed to tablets, capsules, premixes, granules, solutions, or injectables, but downstream manufacturers must still perform route-specific validation because the API release tests do not replace finished-product tests. For capsule filling, the powder is processed on a tamping-pin or dosator machine using the bulk density and flow data from Ph. Eur. 2.9.34 to set compression stations. For low-dose capsules, pre-blending with a directly compressible filler such as microcrystalline cellulose or lactose monohydrate improves dose weight consistency. The blend should be sampled at the beginning, middle, and end of the filling run; in-process percent relative standard deviation limits for capsule weight are commonly set at 2.0% or below for powders with good flow, but the specific acceptance limit is formulation-dependent. If the powder is filled in hard gelatin capsules, moisture uptake above 60% RH may cause softening or cross-linking of the shell; therefore the filling suite should be maintained at or below 45% RH for capsules containing hygroscopic formulations.

If the Same Veterinary API Is Supplied for Feed Premix and Sterile Injectable Applications, What Specification Divergence Is Required?

Across feed-premix and injectable applications, specification ceilings diverge. A feed premix API may be released with a higher total aerobic count and a higher endotoxin level because the target species and route of exposure are different; a sterile injectable API must be controlled to a low bioburden and a low endotoxin content suitable for the final dosage form. Jupi Powder is supplied as a single multi-route veterinary grade, meaning that the release specification is designed to meet the more restrictive injectable and solution requirements where applicable, while still permitting feed and oral powder processing. The manufacturer’s batch certificate therefore lists the route-specific results separately, not as a single undifferentiated set of values. If a supplier offers an oral-grade API with unspecified polymorph content, the risk of conversion during high-shear granulation or terminal sterilization is not controlled. After milling and before release, polymorph identity is measured by Ph. Eur. 2.9.33 X-ray powder diffraction, and the batch record confirms that the same crystalline form is present before and after representative processing steps. Differences between suppliers frequently appear at the level of residual solvent profile, particle morphology after micronization, and the percentage of fines below 10 µm. In injectable reconstitution, a high fines fraction accelerates dissolution but may increase surface area and chemical instability; in premix blending, excessive fines may segregate and create dust exposure during transfer. Jupi Powder is controlled for fines by laser diffraction, and the certificate of analysis reports d10, d50, and d90 for each batch. Published data for the exact d90 specification of the current lot are limited; the batch certificate should be consulted before setting process parameters. When pneumatic transfer is used to convey the powder into tablet press feed hoppers or premix blenders, the system should be designed with the measured bulk density and particle-size distribution from Ph. Eur. 2.9.34 and Ph. Eur. 2.9.31. Lean-phase conveying with velocities above 15 m/s can increase fines generation by particle–wall impact; dense-phase conveying below 10 m/s may be preferred for friable powders, but the optimal mode must be confirmed in a pilot campaign. Dust explosion risk is assessed using ISO/IEC 80079-20-2 test data or equivalent NFPA methods; if no test data exist for the finished blend, the manufacturer’s powder safety report should be consulted. Transfer lines and receiving bins are grounded, and the conveying gas is conditioned to below 60% RH unless the product’s moisture sorption isotherm demonstrates a higher safe limit.